{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:49:08Z","timestamp":1782470948567,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12185-026-04179-1","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:36:58Z","timestamp":1770781018000},"page":"885-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Threshold for cytomegalovirus DNA PCR for preemptive treatment after allogeneic stem cell transplantation"],"prefix":"10.1007","volume":"123","author":[{"given":"Shin-ichiro","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunto","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuka","family":"Furuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Gomyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kusuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"3","key":"4179_CR1","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119\u201327.","journal-title":"Lancet Haematol"},{"issue":"19","key":"4179_CR2","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","volume":"122","author":"M Schmidt-Hieber","year":"2013","unstructured":"Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood. 2013;122(19):3359\u201364.","journal-title":"Blood"},{"issue":"1","key":"4179_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","volume":"7","author":"J Styczynski","year":"2018","unstructured":"Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther. 2018;7(1):1\u201316.","journal-title":"Infect Dis Ther"},{"issue":"20","key":"4179_CR4","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427\u201338.","journal-title":"Blood"},{"issue":"10","key":"4179_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jtct.2025.06.025","volume":"31","author":"F Khawaja","year":"2025","unstructured":"Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, et al. American society for transplantation and cellular therapy series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients. Transplant Cell Ther. 2025;31(10):727\u201341.","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"4179_CR6","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","volume":"25","author":"P Ljungman","year":"2025","unstructured":"Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025;25(8):e451\u201362.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4179_CR7","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.065","volume":"16","author":"JL Pi\u00f1ana","year":"2024","unstructured":"Pi\u00f1ana JL, Gim\u00e9nez E, V\u00e1zquez L, Marcos M, Guerreiro M, Duarte R, et al. Update on cytomegalovirus infection management in allogeneic hematopoietic stem cell transplant recipients. a consensus document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC). Mediterr J Hematol Infect Dis. 2024;16(1):e2024065.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"4","key":"4179_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.bmt.1702805","volume":"27","author":"Y Kanda","year":"2001","unstructured":"Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant. 2001;27(4):437\u201344.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"4179_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bmt.1702227","volume":"25","author":"T Mori","year":"2000","unstructured":"Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25(7):765\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"4179_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073754","volume":"8","author":"K Sakamoto","year":"2013","unstructured":"Sakamoto K, Nakasone H, Wada H, Yamasaki R, Ishihara Y, Kawamura K, et al. Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. PLoS ONE. 2013;8(9):e73754.","journal-title":"PLoS ONE"},{"key":"4179_CR11","unstructured":"Japanese Society for Transplantation and Cellular Therapy. Hematopoietic Cell Transplantation Guidelines. Prevention and treatment of viral infections: cytomegalovirus infection, 5th edition (Sep. 2024) [in Japanese]. [Accessed 1 July 2025]."},{"issue":"4","key":"4179_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","volume":"44","author":"JF Fryer","year":"2016","unstructured":"Fryer JF, Heath AB, Minor PD. A collaborative study to establish the 1st WHO international standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals. 2016;44(4):242\u201351.","journal-title":"Biologicals"},{"issue":"4","key":"4179_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","volume":"24","author":"JF Camargo","year":"2018","unstructured":"Camargo JF, Kimble E, Rosa R, Shimose LA, Bueno MX, Jeyakumar N, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(4):806\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4179_CR14","first-page":"1750","volume":"28","author":"T Kurihara","year":"1996","unstructured":"Kurihara T, Hayashi J, Ito A, Asai T. CMV antigenemia assay using indirect ALP-immunostaining in bone marrow transplant recipients. Transplant Proc. 1996;28(3):1750\u20133.","journal-title":"Transplant Proc"},{"key":"4179_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.883","author":"S Kawamura","year":"2025","unstructured":"Kawamura S, Fujiwara SI, Kimura SI, Takeshita J, Nakasone H, Yoshimura K, et al. Risk-adapted letermovir prophylaxis based on a scoring system predicting a higher burden of cytomegalovirus exposure after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.883.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"4179_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4179_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3343\/alm.2020.40.1.88","volume":"40","author":"S Choi","year":"2020","unstructured":"Choi S, Kim YJ, Yoo KH, Sung KW, Koo HH, Kim SJ, et al. Relationship of circulating cytomegalovirus levels obtained through antigenemia testing and quantitative PCR differs between children and adults. Ann Lab Med. 2020;40(1):88\u201391.","journal-title":"Ann Lab Med"},{"issue":"2","key":"4179_CR18","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1097\/MPH.0000000000002467","volume":"45","author":"B Ahn","year":"2023","unstructured":"Ahn B, Yun KW, Hong KT, Choi JY, Kang HJ, Seong MW, et al. Threshold of quantitative cytomegalovirus DNA PCR for preemptive treatment in pediatric hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol. 2023;45(2):e200\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"4179_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/bmt.2009.337","volume":"45","author":"Y Kanda","year":"2010","unstructured":"Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S, et al. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant. 2010;45(8):1325\u201332.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"4179_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/jmv.25426","volume":"91","author":"A Talaya","year":"2019","unstructured":"Talaya A, Gim\u00e9nez E, Pi\u00f1ana JL, Albert E, Hern\u00e1ndez-Boluda JC, P\u00e9rez A, et al. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: virological features and clinical outcomes. J Med Virol. 2019;91(6):1128\u201335.","journal-title":"J Med Virol"},{"issue":"12","key":"4179_CR21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jiac.2024.05.010","volume":"30","author":"M Walling","year":"2024","unstructured":"Walling M, Seago K, Dillaman M, Yingling S, Wen S, Veltri L, et al. Analysis of spontaneous cytomegalovirus clearance after low level reactivation using a pre-emptive treatment threshold of 4000 IU\/mL in allogeneic hematopoietic cell transplant recipients. J Infect Chemother. 2024;30(12):1233\u20136.","journal-title":"J Infect Chemother"},{"issue":"3","key":"4179_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13548","volume":"23","author":"J Lindsay","year":"2021","unstructured":"Lindsay J, Othman J, Kerridge I, Fay K, Stevenson W, Arthur C, et al. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: pre-transplant predictors of survival, reactivation, and spontaneous clearance. Transpl Infect Dis. 2021;23(3):e13548.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"4179_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02421-y","volume":"21","author":"HY AlQahtani","year":"2024","unstructured":"AlQahtani HY, AlSuhebany N, Alowais SA, AlShehri B, Althemery A, Alghanim A, et al. Characterization of recurrent cytomegalovirus reactivations post allogenic stem cell transplantation in a population with high seropositivity. Virol J. 2024;21(1):149.","journal-title":"Virol J"},{"key":"4179_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14222523","author":"C Gupta","year":"2024","unstructured":"Gupta C, Mundan NG, Das S, Jawed A, Dar SA, Dailah HG. Cytomegalovirus infections in hematopoietic stem cell transplant: moving beyond molecular diagnostics to immunodiagnostics. Diagnostics. 2024. https:\/\/doi.org\/10.3390\/diagnostics14222523.","journal-title":"Diagnostics"},{"issue":"5","key":"4179_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.bbmt.2020.01.015","volume":"26","author":"D Huntley","year":"2020","unstructured":"Huntley D, Talaya A, Gim\u00e9nez E, Mart\u00ednez A, Hern\u00e1ndez-Boluda JC, Hernani R, et al. Features of cytomegalovirus DNAemia blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transplant. 2020;26(5):972\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"4179_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000787","volume":"4","author":"IP Lodding","year":"2018","unstructured":"Lodding IP, Mocroft A, da Cunha BC, Gustafsson F, Iversen M, Kirkby N, et al. Impact of CMV PCR Blips in recipients of solid organ and hematopoietic stem cell transplantation. Transplant Direct. 2018;4(6):e355.","journal-title":"Transplant Direct"},{"issue":"3","key":"4179_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/cid\/cix804","volume":"66","author":"JA Hill","year":"2018","unstructured":"Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, et al. Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2018;66(3):368\u201375.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4179_CR28","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1111\/ajt.16450","volume":"21","author":"I Cassaniti","year":"2021","unstructured":"Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21(4):1622\u20138.","journal-title":"Am J Transplant"},{"key":"4179_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/v15091884","author":"D Nho","year":"2023","unstructured":"Nho D, Lee R, Cho SY, Lee DG, Kim EJ, Park S, et al. Cytomegalovirus infection after allogeneic hematopoietic cell transplantation under 100-day letermovir prophylaxis: a real-world 1-year follow-up study. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15091884.","journal-title":"Viruses"},{"issue":"19","key":"4179_CR30","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","volume":"135","author":"H Einsele","year":"2020","unstructured":"Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135(19):1619\u201329.","journal-title":"Blood"},{"issue":"25","key":"4179_CR31","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344.","journal-title":"N Engl J Med"},{"issue":"10","key":"4179_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13666","volume":"33","author":"C Girmenia","year":"2019","unstructured":"Girmenia C, Lazzarotto T, Bonifazi F, Patriarca F, Irrera G, Ciceri F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019;33(10):e13666.","journal-title":"Clin Transplant"},{"issue":"2","key":"4179_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","volume":"58","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Ljungman P, Tridello G, Mikulska M, Wendel L, Styczynski J, et al. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working pary of EBMT. Bone Marrow Transplant. 2023;58(2):203\u20138.","journal-title":"Bone Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04179-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04179-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04179-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:09:10Z","timestamp":1782468550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04179-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4179"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04179-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S-i. F. has received honoraria from Merck & Co., Inc., S-i. K. has received honoraria from Merck & Co., Inc. (MSD), and Takeda Pharmaceutical Company Limited., H. N. has received research grants from JCR Pharmaceuticals Co., Ltd., Kyowa Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Terumo Corporation and honoraria from Merck & Co., Inc. (MSD), Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sanofi S.A., Meiji Seika Pharma Co., Ltd., Bristol-Myers Squibb Company, and Asahi Kasei Pharma Corporation., S. Kako has received honoraria from Takeda Pharmaceutical Company Limited., Y.K. is an associate editor of IJH and has received honoraria from Merck & Co., Inc., and Takeda Pharmaceutical Company Limited., and the remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Participants were informed about the study through an opt-out approach, where detailed information was provided, and they were given the opportunity to decline participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}